Hydroxy-alkenals from the Peroxidation of N-3 and N-6 Fatty Acids and Urinary Metabolites
Overview
Authors
Affiliations
4-Hydroxy-2E-hexenal (4-HHE) and 4-hydroxy-2E-nonenal (4-HNE) have been characterized as prominent by-products of n-3 and n-6 hydroperoxy derivatives of n-3 and n-6 fatty acids, respectively. We also have characterized the homolog 4-hydroxy-2E,6Z-dodecadienal (4-HDDE) as a specific by-product of the 12-lipoxygenase product of arachidonic acid 12-hydroperoxy-eicosatetraenoate (12-HpETE). The three hydroxy-alkenals have been found in human plasma with 4-HHE being the most prominent followed by 4-HNE. They were found increased in tissues submitted to oxidative stress, according to the fatty acid characteristic of those tissues, e.g., 4-HNE and 4-HDDE in blood platelets and 4-HHE in the retina. We have shown they covalently bind to the primary amine moiety of ethanolamine phospholipids (PE), especially the plasmalogen subclass, with the highest hydrophobic alkenal (4-HDDE) being the most reactive. Their carboxylic acid metabolites, 4-hydroxy-2E-hexenoic acid (4-HHA), 4-hydroxy-2E-nonenoic acid (4-HNA) and 4-hydroxy-2E,6Z-dodecadienoic acid (4-HDDA), respectively, were found in human urine and measured in higher amounts in situations in which oxidative stress has been reported such as aging and diabetes. As reported above with their hydroxy-alkenals precursors, 4-HHA proved to be the most prominent followed by 4-HNA. Altogether, the three hydroxy-alkenals, either in their free form or bound to membrane PE, may be considered as specific markers of lipid peroxidation able to discriminate between n-3 and n-6 fatty acids. This is corroborated by the measurement of their urinary carboxylic acid metabolites.
Ceja-Galicia Z, Cespedes-Acuna C, El-Hafidi M Int J Mol Sci. 2025; 26(2).
PMID: 39859502 PMC: 11765695. DOI: 10.3390/ijms26020788.
Jokesch P, Oskolkova O, Fedorova M, Gesslbauer B, Bochkov V J Lipid Res. 2025; 66(2):100742.
PMID: 39778770 PMC: 11841071. DOI: 10.1016/j.jlr.2025.100742.
Fadaei R, Bernstein A, Jenkins A, Pickens A, Zarrow J, Alli-Oluwafuyi A bioRxiv. 2024; .
PMID: 39554116 PMC: 11565945. DOI: 10.1101/2024.10.30.621135.
Modifications of Blood Molecular Components after Treatment with Low Ozone Concentrations.
Inguscio C, Cisterna B, Carton F, Barberis E, Manfredi M, Malatesta M Int J Mol Sci. 2023; 24(24).
PMID: 38139004 PMC: 10742958. DOI: 10.3390/ijms242417175.
Boldeanu L, Vaduva C, Caragea D, Novac M, Manasia M, Silosi I Life (Basel). 2023; 13(12).
PMID: 38137843 PMC: 10745027. DOI: 10.3390/life13122242.